- Home
- ILMN vs XPO Comparison
ILMN vs XPO Comparison
Compare ILMN & XPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- XPO
- Stock Information
- Founded
- ILMN 1998
- XPO 2000
- Country
- ILMN United States
- XPO United States
- Employees
- ILMN N/A
- XPO N/A
- Industry
- ILMN Medical Specialities
- XPO Transportation Services
- Sector
- ILMN Health Care
- XPO Consumer Discretionary
- Exchange
- ILMN Nasdaq
- XPO Nasdaq
- Market Cap
- ILMN 15.9B
- XPO 14.3B
- IPO Year
- ILMN 2000
- XPO N/A
- Fundamental
- Price
- ILMN $78.39
- XPO $109.12
- Analyst Decision
- ILMN Buy
- XPO Strong Buy
- Analyst Count
- ILMN 18
- XPO 17
- Target Price
- ILMN $141.94
- XPO $153.76
- AVG Volume (30 Days)
- ILMN 2.2M
- XPO 1.7M
- Earning Date
- ILMN 05-01-2025
- XPO 05-02-2025
- Dividend Yield
- ILMN N/A
- XPO N/A
- EPS Growth
- ILMN N/A
- XPO 102.56
- EPS
- ILMN N/A
- XPO 3.23
- Revenue
- ILMN $4,372,000,000.00
- XPO $8,072,000,000.00
- Revenue This Year
- ILMN $1.49
- XPO $3.99
- Revenue Next Year
- ILMN $5.03
- XPO $6.00
- P/E Ratio
- ILMN N/A
- XPO $33.72
- Revenue Growth
- ILMN N/A
- XPO 4.24
- 52 Week Low
- ILMN $77.54
- XPO $97.03
- 52 Week High
- ILMN $156.66
- XPO $161.00
- Technical
- Relative Strength Index (RSI)
- ILMN 23.92
- XPO 41.31
- Support Level
- ILMN $77.54
- XPO $103.59
- Resistance Level
- ILMN $89.95
- XPO $114.88
- Average True Range (ATR)
- ILMN 2.72
- XPO 4.15
- MACD
- ILMN 0.50
- XPO 0.92
- Stochastic Oscillator
- ILMN 6.85
- XPO 48.98
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
About XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. we estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. we believe XPO intends to divest its European trucking division once it finds the right buyer.